LAUSR

Key Points Question Can casirivimab and imdevimab effectively reduce the viral load of SARS-CoV-2 with lower doses and a subcutaneous route of administration? Findings In this phase 2 randomized clinical trial of outpatients with SARS-CoV-2, all casirivimab and imdevimab doses and routes of administration showed statistically significant and comparable reductions in viral load through day 7 vs placebo in those who were seronegative at baseline. Meaning These findings, combined with the results from additional studies examining clinical efficacy, justify lowering the dose of casirivimab and imdevimab from 2400 mg to 1200 mg and suggest that subcutaneous administration is a viable alternative to intravenous administration.